Clinical Trials Logo

Clinical Trial Summary

This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood [CB]-NK-TGF-betaR2-/NR3C1-) in treating patients with glioblastoma that has come back (recurrent). CB-NK-TGF-betaR2-/NR3C1- cells are genetically changed immune cells that may help to control the disease.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine the safety and tolerability of escalating doses of off-the-shelf CB-NK-TGF-betaR2-/NR3C1- in patients with recurrent glioblastoma (GBM), occurrence of dose limiting toxicities (DLTs) and determine the maximum tolerated dose (MTD). (Group 1) II. To evaluate the immunological phenotype and anti-tumor function of NK cells in resected tumor tissue after treatment with CB-NK-TGF-betaR2-/NR3C1- in the surgical expansion group. (Group 2) SECONDARY OBJECTIVE: I. To determine response as measured by Response Assessment in Neuro-Oncology (RANO), duration of clinical response, progression free survival (PFS), time to progression (TTP), and overall survival (OS). EXPLORATORY OBJECTIVES: I. Monitoring immune responses following CB-NK-TGF-betaR2-/NR3C1- dosing, in vivo persistence and expansion of CB-NK-TGF-betaR2-/NR3C1- during treatment, characterization of immune cell subpopulations in the peripheral blood, serum analysis of immune correlates, alloreactivity characterization, and anti-HLA antibody analysis, and CB-NK-TGF-betaR2-/NR3C1- trafficking in tumor microenvironments in the surgical expansion cohort. II. Tumor tissue from surgical resection will be further analyzed for immune infiltrates, fibrosis, and tumor microenvironment. OUTLINE: This is a dose-escalation study followed by a dose-expansion study. Patients are assigned to 1 of 2 groups. GROUP 1: Patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes weekly for up to 8 doses in the absence of disease progression or unacceptable toxicity. GROUP 2: Patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes on days 0, 7, and 14. Patients undergo standard of care surgical resection on day 15. Beginning 2 weeks after surgery, patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes weekly for up to 5 doses (total of 8 doses) in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 7, 30, and 90 days. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04991870
Study type Interventional
Source M.D. Anderson Cancer Center
Contact Shiao-Pei Weathers, MD
Phone 713-792-2883
Email sweathers@mdanderson.org
Status Recruiting
Phase Phase 1
Start date April 28, 2023
Completion date January 31, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05039281 - Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma Phase 1/Phase 2
Withdrawn NCT05017610 - Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma Early Phase 1
Completed NCT03360708 - Vaccine Therapy in Treating Patients With Recurrent Glioblastoma Early Phase 1
Terminated NCT03283631 - Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM Phase 1
Recruiting NCT05139056 - Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas Phase 1
Withdrawn NCT04854044 - ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma Phase 1
Active, not recruiting NCT02192359 - Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Phase 1
Recruiting NCT05465954 - Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma Phase 2
Recruiting NCT03896568 - MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma Phase 1
Active, not recruiting NCT00102648 - Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide Phase 1
Recruiting NCT04477200 - Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma Phase 1
Active, not recruiting NCT02337686 - Pembrolizumab in Treating Patients With Recurrent Glioblastoma Phase 2
Completed NCT00883298 - Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme Phase 2